Orlando-Intravitreal triamcinolone acetonide may be a therapeutic option for stabilizing or improving vision in eyes with exudative age-related macular degeneration (AMD), said Jost B. Jonas, MD, at the annual meeting of the American Academy of Ophthalmology.
New York-Intravitreal triamcinolone acetonide appears to be a useful adjunct to photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) in the treatment of eyes with choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), said Richard F. Spaide, MD, at the Macula 2003 meeting here.
New York-The European Commission is wrapping up its investigation into a proposed merger of pharmaceutical giants Pfizer Inc. and Pharmacia Corp.
Editor's Note: Approximately 25% of all new cases of blindness are attributed to diabetes, and it is the second leading cause of blindness in people under the age of 65 in the United States.
Orlando-Contact lens-assisted, pharmacologically induced keratosteepening (CLAPIKS) is a safe, simple, and often effective modality for treating hyperopia present after laser vision correction surgery, said Jay McDonald II, MD, during the refractive surgery subspecialty day meeting prior to the American Academy of Ophthalmol-ogy annual meeting.
Sewickley, PA-Sodium hyaluronate 1.6% (Amvisc Plus, Bausch & Lomb) offers the right balance of desired viscoelastic properties, making it useful during each stage of cat-aract surgery and an excellent choice for nearly all phacoemulsification cases, agree cataract surgeons Richard A. Bowers, MD, and Andrew Tharp, MD.
Novartis Ophthalmics and Valley Forge Pharmaceuticals Inc. have entered into a licensing agreement for a novel eye medication for myopia, which in phase II clinical trials reduced progression of the disease by 50% in the first 12 months of therapy.
The FDA approval of cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) Dec. 26 marked a landmark for ophthalmology. The eye drop therapy for moderate to severe keratoconjunctivitis sicca is unique in that it treats the inflammatory process that causes the condition, and not just its symptoms.
Defining its role: Intraocular corticosteroid injections best reservedfor vision-threatening disease in uveitis patients
Editor's Note: In this month's column,a panel of experts offers tips on when and how to administer intraocular injectionsof corticosteroid for patients with uveitis.
FDA OKs trials of laser reversal of presbyopia